Supportive care

Phase 3Small molecule

BeiGene

Supportive care is one of 107 small molecule programs targeting Acute Kidney Injury. It is currently in Phase 3.

Indications

Total Trials

Active Trials

106

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Kidney InjuryActive, not recruiting

COVID-19Active, not recruiting

Acute Respiratory Distress SyndromeActive, not recruiting

Acute Kidney InjuryPreclinical

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Acute Respiratory Distress SyndromePhase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Supportive care

BeiGene

Phase 3

1 2

Spikevax

Moderna

Preclinical

21 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Stivarga

Bayer

Preclinical

1 7

Aimovig

Amgen

Preclinical

1 8

Aldactone

Pfizer

Preclinical

1 9

Nexavar

Bayer

Preclinical

1 10

Singulair

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Not yet recruiting

Acute Respiratory Distress Syndrome

NCT06640777

Clinical

Trials by Indication[1]

Acute Kidney Injury1 trial

Comparison of Early Caffeine Administration Vs Supportive Therapy in Preventing Acute Kidney Injury

Recruiting·MMuhammad Aamir Latif·N/A·NCT07305935·236 enrolled

Acute Respiratory Distress Syndrome1 trial

Efficacy and Safety of LEAF-4L6715 for Acute Respiratory Distress Syndrome

Not yet recruiting·LLEAF4Life, Inc.·Phase 3·NCT06640777·310 enrolled

COVID-191 trial

Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants

Completed· BeiGene logo

BeiGene·Phase 2·NCT04382586·63 enrolled

HSCT1 trial

The Use of Eltrombopag Post HSCT in BMFD

Completed·TThe First Affiliated Hospital of Soochow University·Phase 2/3·NCT05466201·118 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Supportive care. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Supportive care compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Supportive care. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BeiGene company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BeiGene

Supportive care

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Acute Kidney Injury1 trial

Acute Respiratory Distress Syndrome1 trial

COVID-191 trial

HSCT1 trial

References

Drug Info

Quick Facts

Related News